Inadequate evidence for a revised definition of postherpetic neuralgia (PHN)

Pain

Volumn 128, Issue 1-2, 2007, Pages 189-190

  Dworkin, Robert H ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIVIRUS AGENT;

DISEASE DURATION; EXPERIMENTAL THERAPY; HERPES ZOSTER; HUMAN; INTERVENTION STUDY; LETTER; MEDICAL ILLUSTRATION; MORBIDITY; PAIN ASSESSMENT; PHYSICIAN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; SAMPLE SIZE; VALIDITY;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; FEMALE; HERPES ZOSTER; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33846850504     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.12.001     Document Type: Letter

References (11)

1. Beutner K.R., Friedman D.J., Forszpaniak C., Andersen P.L., and Wood M.J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39 (1995) 1546-1553
2. Coplan P.M., Schmader K., Nikas A., Chan I.S.F., Choo P., Levin M.J., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 5 (2004) 344-356
3. Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 44 Suppl 1 (2007) S1-S26
4. Lydick E., Epstein R., Himmelberger D., and White C.J. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 45 Suppl. 8 (1995) S52-S53
5. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
6. Thyregod H.G., Rowbotham M.C., Peters M., Possehn J., Berro M., and Petersen K.L. Natural history of pain following herpes zoster. Pain 128 (2007) 148-156
7. Turk D.C., Dworkin R.H., Burke L.B., Gershon R., Rothman M., Scott J., et al. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 125 (2006) 208-215
8. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf, February 2006.
9. Wassilew S.W. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients: a randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 19 (2005) 47-55
10. Wassilew S.W., and Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 59 (2003) 49-56
11. Wood M.J., Kay R., Dworkin R.H., Soong S.J., and Whitley R.J. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 22 (1996) 341-347